Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin
- PMID: 10589744
Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin
Abstract
Overexpression of P-glycoprotein (Pgp), a multidrug transporter encoded by the MDR1 gene, is associated with chemoresistance in some human solid tumor malignancies. To date, analyses of MDR1 levels in solid tumors have examined constitutive increases in expression at relapse. In the present study, we have evaluated the acute induction of MDR1 gene expression in a solid human tumor as a function of time in response to in vivo exposure to chemotherapy. Five patients with unresectable sarcoma pulmonary metastases underwent isolated single lung perfusion with doxorubicin. Relative MDR1 gene expression was measured in metastatic tumor nodules and normal lung specimens after initiation of chemoperfusion. In four of five patients, a 3-15-fold (median, 6.8) increase in MDR1 RNA levels was detected in tumors at 50 min after administration of doxorubicin. In contrast, normal lung samples had very low levels of MDR1 RNA prior to perfusion, and no acute increases were observed after therapy. These findings demonstrate, for the first time, that MDR1 gene expression can be rapidly activated in human tumors after transient in vivo exposure to cytotoxic chemotherapy.
Comment in
-
Drug resistance: still on the learning curve.Clin Cancer Res. 1999 Nov;5(11):3346-8. Clin Cancer Res. 1999. PMID: 10589742 No abstract available.
Similar articles
-
Expression of the human multidrug resistance gene (MDR1) and prognostic correlation in human osteogenic sarcoma.Tokai J Exp Clin Med. 1994 Sep;19(1-2):39-46. Tokai J Exp Clin Med. 1994. PMID: 7660382
-
MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment.Clin Cancer Res. 2000 Dec;6(12):4618-27. Clin Cancer Res. 2000. PMID: 11156211
-
A case of malignant schwannoma with overexpression of multidrug resistance gene (MDR1) after chemotherapy.Anticancer Res. 1997 May-Jun;17(3C):2273-7. Anticancer Res. 1997. PMID: 9216701
-
Mdr1 promoter-driven tumor necrosis factor-alpha expression for a chemotherapy-controllable combined in vivo gene therapy and chemotherapy of tumors.Cancer Gene Ther. 2000 Jun;7(6):893-900. doi: 10.1038/sj.cgt.7700196. Cancer Gene Ther. 2000. PMID: 10880020
-
Treatment of the patient with lung metastases.Curr Probl Surg. 1996 Nov;33(11):881-952. doi: 10.1016/s0011-3840(96)80003-7. Curr Probl Surg. 1996. PMID: 8909328 Review. No abstract available.
Cited by
-
Enhancement of cellular uptake and cytotoxicity of curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells.Acta Pharmacol Sin. 2012 Jun;33(6):823-31. doi: 10.1038/aps.2012.34. Epub 2012 May 14. Acta Pharmacol Sin. 2012. PMID: 22580738 Free PMC article.
-
MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.Neoplasia. 2010 Aug;12(8):628-36. doi: 10.1593/neo.10402. Neoplasia. 2010. PMID: 20689757 Free PMC article. Clinical Trial.
-
Nanoparticles: a promising modality in the treatment of sarcomas.Pharm Res. 2011 Feb;28(2):260-72. doi: 10.1007/s11095-010-0173-z. Epub 2010 May 27. Pharm Res. 2011. PMID: 20505985 Review.
-
ET-743.Drugs. 2002;62(8):1185-92; discussion 1193-4. doi: 10.2165/00003495-200262080-00005. Drugs. 2002. PMID: 12010079 Review.
-
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities.Adv Drug Deliv Rev. 2013 Nov;65(13-14):1731-47. doi: 10.1016/j.addr.2013.09.001. Epub 2013 Sep 10. Adv Drug Deliv Rev. 2013. PMID: 24036273 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Miscellaneous